Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Single Dose Crossover Comparison of the Safety, Tolerability, and Pharmacokinetic Profile of CTP-692 Versus D-Serine

Trial Profile

A Randomized Single Dose Crossover Comparison of the Safety, Tolerability, and Pharmacokinetic Profile of CTP-692 Versus D-Serine

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Dec 2018

At a glance

  • Drugs Deuterated D-Serine (Primary) ; D-serine
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Concert Pharmaceuticals
  • Most Recent Events

    • 17 Dec 2019 According to a Concert Pharmaceuticals media release, initial data from this trial is expected in the first quarter of 2019.
    • 17 Dec 2018 Status changed from planning to recruiting.
    • 02 Aug 2018 According to a Concert Pharmaceuticals media release, the company expects to initiate this trial the fourth quarter 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top